{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:44:47Z","timestamp":1791819887899,"version":"4.3.4"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.semcancer.2026.102619","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:41:10Z","timestamp":1789882870000},"page":"102619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Precision oncology in GI-cancers: Mechanisms of action, indications and ongoing strategies to overcome primary and secondary resistance"],"prefix":"10.1016","volume":"126","author":[{"given":"Laia","family":"Aceituno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Valenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreste","family":"Segatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Saborowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.semcancer.2026.102619_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.","volume":"32","year":"2017","journal-title":"Cancer Cell."},{"issue":"10272","key":"10.1016\/j.semcancer.2026.102619_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.semcancer.2026.102619_bib3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","article-title":"ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal\u2013Anal Task Forces whitepaper","volume":"17","author":"Dasari","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.semcancer.2026.102619_bib4","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.semcancer.2026.102619_bib5","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.semcancer.2026.102619_bib6","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2026.102619_bib7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2026.102619_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting Alterations in the RAF-MEK Pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2026.102619_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"2","key":"10.1016\/j.semcancer.2026.102619_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2026.102619_bib12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"10.1016\/j.semcancer.2026.102619_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-med-042921-024707","article-title":"FGFR2 Inhibition in Cholangiocarcinoma","volume":"74","author":"Vogel","year":"2023","journal-title":"Annu. Rev. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2026.102619_bib14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.semcancer.2026.102619_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up \u2606","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: Ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.semcancer.2026.102619_bib17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"4_","key":"10.1016\/j.semcancer.2026.102619_bib18","article-title":"FIDES-01, a phase II study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M\/A)","volume":"38","author":"Javle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2026.102619_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41698-024-00683-x","article-title":"FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer","volume":"8","author":"Stein","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.semcancer.2026.102619_bib21","article-title":"Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial","author":"Bekaii-Saab","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"July","key":"10.1016\/j.semcancer.2026.102619_bib22","first-page":"1","article-title":"Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma","volume":"121","author":"Lamarca","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.semcancer.2026.102619_bib23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-25669-1","article-title":"Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma","volume":"8","author":"Simbolo","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.semcancer.2026.102619_bib25","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.31799","article-title":"The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma","volume":"74","author":"Kendre","year":"2021","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.semcancer.2026.102619_bib26","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.semcancer.2026.102619_bib27","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1\u2013FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rod\u00f3n","year":"2024","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2026.102619_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/mcs.a004002","article-title":"Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy","volume":"5","author":"Krook","year":"2019","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"issue":"3","key":"10.1016\/j.semcancer.2026.102619_bib29","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.semcancer.2026.102619_bib30","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2023.10.041","article-title":"Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma","volume":"80","author":"DiPeri","year":"2024","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.semcancer.2026.102619_bib31","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1021\/acsmedchemlett.9b00427","article-title":"Second-Generation FGFR Inhibitors for the Treatment of Cancers Harboring Mutated FGFRs","volume":"10","author":"Abdel-Magid","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.semcancer.2026.102619_bib32","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/2159-8290.CD-12-0569","article-title":"Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer","volume":"3","author":"Herrera-Abreu","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2026.102619_bib33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.semcancer.2022.12.002","article-title":"Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics","volume":"88","author":"Zhang","year":"2023","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.semcancer.2026.102619_bib34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/PO.20.00178","article-title":"Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations","author":"Varghese","year":"2021","journal-title":"JCO Precis. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2026.102619_bib35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.11.017","article-title":"Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2026.102619_bib36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","article-title":"A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2026.102619_bib37","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.11.017","article-title":"Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2026.102619_bib38","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"16_","key":"10.1016\/j.semcancer.2026.102619_bib39","article-title":"Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors","volume":"41","author":"Borad","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.102619_bib40","article-title":"Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial","author":"Javle","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"4_","key":"10.1016\/j.semcancer.2026.102619_bib41","article-title":"Tinengotinib in patients with advanced, metastatic cholangiocarcinoma: Overall survival results and biomarker correlative analysis from a phase 2 clinical trial","volume":"43","author":"Fountzilas","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/hep.30127","article-title":"HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma","volume":"69","author":"Lamberti","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.semcancer.2026.102619_bib43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jhep.2021.02.032","article-title":"FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma","volume":"75","author":"Cristinziano","year":"2021","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.semcancer.2026.102619_bib44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2026.102619_bib45","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2026.102619_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00544","article-title":"Comprehensive Immunogenomic Profiling of IDH1- \/ 2 -Altered Cholangiocarcinoma","author":"Makawita","year":"2024","journal-title":"JCO Precis. Oncol."},{"issue":"MAR","key":"10.1016\/j.semcancer.2026.102619_bib47","first-page":"1","article-title":"Molecular imaging of metabolic reprograming in mutant IDH cells","volume":"6","author":"Viswanath","year":"2016","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.semcancer.2026.102619_bib48","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell. Rep."},{"issue":"10","key":"10.1016\/j.semcancer.2026.102619_bib49","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2026.102619_bib50","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib51","first-page":"1","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-32436-4","article-title":"Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors","volume":"13","author":"Reinbold","year":"2022","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.semcancer.2026.102619_bib53","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov."},{"issue":"June","key":"10.1016\/j.semcancer.2026.102619_bib54","first-page":"10","article-title":"The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia","volume":"12","author":"Zhuang","year":"2022","journal-title":"Front. Oncol."},{"issue":"23","key":"10.1016\/j.semcancer.2026.102619_bib55","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1158\/1078-0432.CCR-25-0174","article-title":"Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1\/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations","volume":"31","author":"Harding","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2026.102619_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyag205.036","article-title":"35: A phase 1\/2 trial investigating ivosidenib plus nivolumab and ipilimumab in patients with previously treated mIDH1 CCA","author":"Kelley","year":"2026","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.semcancer.2026.102619_bib57","doi-asserted-by":"crossref","first-page":"799","DOI":"10.32604\/or.2024.045356","article-title":"Targeting KRAS in pancreatic cancer","volume":"32","author":"Stickler","year":"2024","journal-title":"Oncol. Res."},{"issue":"13","key":"10.1016\/j.semcancer.2026.102619_bib58","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.semcancer.2026.102619_bib59","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.semcancer.2026.102619_bib60","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-Human Phase I\/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2026.102619_bib61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.semcancer.2026.102619_bib62","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.semcancer.2026.102619_bib63","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"16_","key":"10.1016\/j.semcancer.2026.102619_bib64","article-title":"Biomarkers of emergent resistance to sotorasib plus panitumumab in KRAS G12C-mutated metastatic colorectal cancer (mCRC) from the randomized, phase 3 CodeBreaK 300 study","volume":"43","author":"Salvatore","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"4_","key":"10.1016\/j.semcancer.2026.102619_bib65","article-title":"Adagrasib (Ada) + cetuximab (Cetux) for KRASG12C-mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1","volume":"43","author":"Yaeger","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.semcancer.2026.102619_bib66","article-title":"Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b)","volume":"43","author":"Strickler","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"4_","key":"10.1016\/j.semcancer.2026.102619_bib67","article-title":"A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C\u2013mutated metastatic colorectal cancer (CodeBreaK 301)","volume":"43","author":"Kim","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.semcancer.2026.102619_bib68","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","article-title":"Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer","volume":"394","author":"Wolpin","year":"2026","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.102619_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107060","article-title":"Outcomes following KRAS(G12C) inhibitor treatment in patients with KRAS(G12C)-mutated solid tumors: A systematic review and meta-analysis","volume":"200","author":"Chen","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.semcancer.2026.102619_bib70","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.lungcan.2019.05.002","article-title":"Impact of KEAP1\/NFE2L2\/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer","volume":"134","author":"Hellyer","year":"2019","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2026.102619_bib71","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.semcancer.2026.102619_bib72","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.annonc.2025.01.020","article-title":"Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors","volume":"36","author":"Riedl","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2026.102619_bib73","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-LB281","article-title":"Abstract LB281: Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies","author":"Kar","year":"2025","journal-title":"Cancer Res."},{"issue":"16_","key":"10.1016\/j.semcancer.2026.102619_bib74","article-title":"Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer","volume":"43","author":"Hollebecque","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2026.102619_bib75","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib76","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41392-025-02274-z","article-title":"Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation","volume":"10","author":"Ruan","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib77","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","article-title":"Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial","volume":"30","author":"Desai","year":"2024","journal-title":"Nat. Med."},{"issue":"30","key":"10.1016\/j.semcancer.2026.102619_bib78","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1038\/s41388-025-03484-z","article-title":"Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer","volume":"44","author":"Jayachandran","year":"2025","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.semcancer.2026.102619_bib79","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-23-3053","article-title":"Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study","volume":"30","author":"Ahn","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.semcancer.2026.102619_bib80","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa2600752","article-title":"Setidegrasib in Advanced Non\u2013Small-Cell Lung Cancer and Pancreatic Cancer","volume":"394","author":"Park","year":"2026","journal-title":"New. Engl. J. Med."},{"issue":"16_","key":"10.1016\/j.semcancer.2026.102619_bib81","volume":"42","author":"Punekar","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.102619_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102905","article-title":"BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives","volume":"134","author":"Napolitano","year":"2025","journal-title":"Cancer Treat. Rev."},{"issue":"34","key":"10.1016\/j.semcancer.2026.102619_bib83","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.semcancer.2026.102619_bib84","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","article-title":"Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer","volume":"33","author":"Corcoran","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.semcancer.2026.102619_bib85","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1158\/0008-5472.CAN-11-1243","article-title":"Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options","volume":"71","author":"Villanueva","year":"2011","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2026.102619_bib86","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","article-title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2026.102619_bib87","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.semcancer.2026.102619_bib88","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/s41591-024-03235-9","article-title":"Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase\u20093 BEACON CRC trial","volume":"30","author":"Kopetz","year":"2024","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2026.102619_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100506","article-title":"Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience","volume":"7","author":"Boccaccino","year":"2022","journal-title":"ESMO Open."},{"issue":"9","key":"10.1016\/j.semcancer.2026.102619_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103696","article-title":"Efficacy and safety of the combination of encorafenib\/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study","volume":"9","author":"Gallois","year":"2024","journal-title":"ESMO Open."},{"issue":"14","key":"10.1016\/j.semcancer.2026.102619_bib91","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.22.01693","article-title":"ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer","volume":"41","author":"Van Cutsem","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.semcancer.2026.102619_bib92","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.semcancer.2026.102619_bib93","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1038\/s41591-022-01976-z","article-title":"RNF43 mutations predict response to anti-BRAF\/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer","volume":"28","author":"Elez","year":"2022","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.semcancer.2026.102619_bib94","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00411","article-title":"Association of RNF43 Genetic Alterations With BRAFV600E and MSIhigh in Colorectal Cancer","author":"Vogel","year":"2024","journal-title":"JCO Precis. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2026.102619_bib95","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2026.102619_bib96","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O'Dwyer","year":"2023","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.semcancer.2026.102619_bib97","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/annonc\/mdu049","article-title":"Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition","volume":"25","author":"Turajlic","year":"2014","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib98","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41698-026-01329-w","article-title":"Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer","volume":"10","author":"Sahin","year":"2026","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.semcancer.2026.102619_bib99","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2016.12.010","article-title":"The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.semcancer.2026.102619_bib100","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s11864-022-01006-7","article-title":"BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies","volume":"23","author":"Zhong","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"issue":"14","key":"10.1016\/j.semcancer.2026.102619_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143540","article-title":"Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma","volume":"13","author":"Maadi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semcancer.2026.102619_bib102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2021.08.007","article-title":"Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era","volume":"60","author":"Mand\u00f3","year":"2021","journal-title":"Breast"},{"issue":"10","key":"10.1016\/j.semcancer.2026.102619_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10100342","article-title":"Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer","volume":"10","author":"Nami","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.semcancer.2026.102619_bib104","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2026.102619_bib105","first-page":"256","article-title":"Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer","volume":"19","author":"Tosi","year":"2020","journal-title":"Clin. Colorectal Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2026.102619_bib106","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2026.102619_bib107","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/14796694.2024.2441101","article-title":"MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer","volume":"21","author":"Strickler","year":"2025","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2026.102619_bib108","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000911","article-title":"Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial","volume":"5","author":"Sartore-Bianchi","year":"2020","journal-title":"ESMO Open."},{"issue":"4","key":"10.1016\/j.semcancer.2026.102619_bib109","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2026.102619_bib110","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.22.02636","article-title":"MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors","volume":"42","author":"Sweeney","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"9742","key":"10.1016\/j.semcancer.2026.102619_bib111","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.semcancer.2026.102619_bib112","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.semcancer.2026.102619_bib113","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","article-title":"Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study","volume":"19","author":"Tabernero","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib114","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10120-022-01335-4","article-title":"Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric\/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial","volume":"26","author":"Tabernero","year":"2023","journal-title":"Gastric Cancer"},{"issue":"7890","key":"10.1016\/j.semcancer.2026.102619_bib115","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"issue":"10418","key":"10.1016\/j.semcancer.2026.102619_bib116","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib117","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1038\/s41467-025-59279-z","article-title":"Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial","volume":"16","author":"Meric-Bernstam","year":"2025","journal-title":"Nat. Commun."},{"issue":"4_","key":"10.1016\/j.semcancer.2026.102619_bib118","article-title":"Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA)","volume":"41","author":"Elimova","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2026.102619_bib119","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S1470-2045(25)00287-6","article-title":"Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study","volume":"26","author":"Elimova","year":"2025","journal-title":"Lancet Oncol."},{"issue":"16_","key":"10.1016\/j.semcancer.2026.102619_bib120","article-title":"Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA): 4-year follow-up of a phase 2 trial","volume":"43","author":"Elimova","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.semcancer.2026.102619_bib121","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2517729","article-title":"Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer","volume":"394","author":"Shitara","year":"2026","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.102619_bib122","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2020.12.005","article-title":"Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial","volume":"145","author":"Rivera","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2026.102619_bib123","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/ijc.33696","volume":"149","author":"Hofheinz","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"32","key":"10.1016\/j.semcancer.2026.102619_bib124","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.22.00380","article-title":"FLOT Versus FLOT\/Trastuzumab\/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group","volume":"40","author":"Hofheinz","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4_","key":"10.1016\/j.semcancer.2026.102619_bib125","article-title":"EORTC-1203 GITC \"INNOVATION\": Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer: Overall survival results","volume":"43","author":"Wagner","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib126","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib127","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"36","key":"10.1016\/j.semcancer.2026.102619_bib128","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.102619_bib129","article-title":"Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01","author":"Pant","year":"2025","journal-title":"JAMA Oncol."},{"issue":"4_","key":"10.1016\/j.semcancer.2026.102619_bib130","article-title":"HERIZON-BTC-302: A phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced\/metastatic biliary tract cancer (BTC)","volume":"43","author":"Harding","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.semcancer.2026.102619_bib131","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16162854","article-title":"Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies","volume":"16","author":"Mo","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.semcancer.2026.102619_bib132","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1158\/1078-0432.CCR-24-2763","article-title":"ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial","volume":"31","author":"Meric-Bernstam","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.semcancer.2026.102619_bib133","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","article-title":"Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study","volume":"18","author":"Thuss-Patience","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2026.102619_bib134","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2026.102619_bib135","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib136","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib137","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"S4","key":"10.1016\/j.semcancer.2026.102619_bib138","first-page":"1069","article-title":"Randomized, open-label, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with rilvegostomig vs standard of care (SOC) in first-line, human epidermal growth factor receptor 2 (HER2)-expressing, locally advanced or metastatic (LA\/m) biliary tr","volume":"35","author":"Ikeda","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib139","article-title":"Deficient mismatch repair\/microsatellite instability-high colorectal cancer: current treatment paradigms, limitations and future perspectives","volume":"5","author":"Storandt","year":"2026","journal-title":"BMJ Oncol."},{"issue":"12","key":"10.1016\/j.semcancer.2026.102619_bib140","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High\/Deficient Mismatch Repair Solid Tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.semcancer.2026.102619_bib141","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1200\/JCO-25-02169","article-title":"Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient\/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP","volume":"44","author":"de la Fouchardi\u00e8re","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.semcancer.2026.102619_bib142","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.semcancer.2026.102619_bib143","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial","volume":"30","author":"de Gooyer","year":"2024","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.semcancer.2026.102619_bib144","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMoa2507874","article-title":"Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer","volume":"394","author":"Sinicrope","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2026.102619_bib145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14796694.2025.2606910","article-title":"A Phase III study of perioperative dostarlimab in patients with dMMR\/MSI-H resectable colon cancer: AZUR-2 study design","volume":"22","author":"Starling","year":"2026","journal-title":"Future Oncol."},{"issue":"23","key":"10.1016\/j.semcancer.2026.102619_bib146","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability\u2013High Advanced Colorectal Cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"New. Engl. J. Med."},{"issue":"10476","key":"10.1016\/j.semcancer.2026.102619_bib147","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semcancer.2026.102619_bib148","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open."},{"issue":"16_","key":"10.1016\/j.semcancer.2026.102619_bib151","article-title":"Real-world outcomes of microsatellite instability-high (MSI-H)\/mismatch repair deficient (dMMR) biliary tract cancers (BTC)","volume":"44","author":"Eluri","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.102619_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115670","article-title":"Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient biliary tract cancer: An AGEO study","volume":"227","author":"Campo-Le-Brun","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2026.102619_bib153","article-title":"PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?","volume":"7","author":"Ricci","year":"2020","journal-title":"Med. (Basel)"},{"issue":"11","key":"10.1016\/j.semcancer.2026.102619_bib154","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2026.102619_bib155","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.semcancer.2026.102619_bib156","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/s41591-026-04299-5","article-title":"Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial","volume":"32","author":"Park","year":"2026","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib157","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41698-025-01009-1","article-title":"A phase II single-arm study of combination pembrolizumab and olaparib in the treatment of patients with advanced biliary tract cancer","volume":"9","author":"Sadagopan","year":"2025","journal-title":"NPJ Precis. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2026.102619_bib158","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2026.102619_bib159","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2026.102619_bib160","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41591-025-04079-7","article-title":"Repotrectinib in NTRK fusion\u2013positive advanced solid tumors: a phase 1\/2 trial","volume":"32","author":"Besse","year":"2026","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.semcancer.2026.102619_bib161","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2026.102619_bib162","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.semcancer.2026.102619_bib163","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2026.102619_bib164","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s43018-024-00819-9","article-title":"Targeting therapy-persistent residual disease","volume":"5","author":"Sun","year":"2024","journal-title":"Nat. Cancer"},{"issue":"7873","key":"10.1016\/j.semcancer.2026.102619_bib165","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","article-title":"Cycling cancer persister cells arise from lineages with distinct programs","volume":"596","author":"Oren","year":"2021","journal-title":"Nature"},{"issue":"7658","key":"10.1016\/j.semcancer.2026.102619_bib166","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature22794","article-title":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","volume":"546","author":"Shaffer","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib167","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"8022","key":"10.1016\/j.semcancer.2026.102619_bib168","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","article-title":"Cellular adaptation to cancer therapy along a resistance continuum","volume":"631","author":"Fran\u00e7a","year":"2024","journal-title":"Nature"},{"issue":"6472","key":"10.1016\/j.semcancer.2026.102619_bib169","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1126\/science.aav4474","article-title":"Adaptive mutability of colorectal cancers in response to targeted therapies","volume":"366","author":"Russo","year":"2019","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.semcancer.2026.102619_bib170","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/2159-8290.CD-21-1168","article-title":"EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.semcancer.2026.102619_bib171","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trecan.2021.11.001","article-title":"Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma","volume":"8","author":"Saborowski","year":"2022","journal-title":"Trends Cancer"},{"issue":"11","key":"10.1016\/j.semcancer.2026.102619_bib172","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/2159-8290.CD-22-0111","article-title":"AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer","volume":"12","author":"Noronha","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.semcancer.2026.102619_bib173","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell."},{"issue":"6","key":"10.1016\/j.semcancer.2026.102619_bib174","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","article-title":"Rational cancer treatment combinations: an urgent clinical need","volume":"78","author":"Boshuizen","year":"2020","journal-title":"Mol. Cell."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X26000866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X26000866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:45:48Z","timestamp":1791816348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X26000866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":174,"alternative-id":["S1044579X26000866"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2026.102619","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision oncology in GI-cancers: Mechanisms of action, indications and ongoing strategies to overcome primary and secondary resistance","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2026.102619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102619"}}